Abstract
Guillain–Barré syndrome (GBS) is a rare cause of severe polyneuropathy in children. We now recognise that GBS is made up of distinct subtypes, with different clinical, electrodiagnostic and pathological findings. The diagnosis of GBS is based on the classical triad of weakness, areflexia and elevated cerebrospinal fluid (CSF) protein without pleocytosis. Early recognition and effective treatment of GBS may reduce morbidity and mortality. The management of GBS includes acute treatment of the paralysis and associated complications, the treatment of the underlying cause, and the long-term rehabilitation of the patient. This article aims to provide a clear evidence-linked care pathway for the management of GBS from the time of presentation to rehabilitation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
